Press release BoxID: 626881 (FDAnews)
  • FDAnews
  • 300 N. Washington St., Suite 200
  • VA 22046 Falls Church
  • Contact person
  • Jeff Grizzel
  • +1 (703) 538-7668

Medical Device Mobile Apps Conference -- Register Today

Smartphone Technology Opens New World for Medical Device Innovation -- and Can of Worms with the FDA / Oct 3 2013 -- 10:00am to 4:00pm EDT / FDAnews Virtual Conference /

(PresseBox) (Falls Church, ) FDAnews has announced details of its next virtual conference, Medical Device Mobile Apps; The Biosense Case; FDA Sends First Warning, to be held on Oct 3 2013.

For details/to register: []


Smartphone technology opens a new world for medical device innovation. It also opens a can of worms with the FDA.
Could you get in trouble?

For instance, a smartphone app that can analyze urine is a really smart app. Indeed it isn't an app at all: It's a medical device. Or is it? That's the question troubling devicemakers everywhere, now that the FDA has made an example of Biosense.

Biosense markets an app called uCheck that checks urine levels of blood, protein and other substances, using dipsticks and an iPhone camera to record and analyze results. The dipsticks are OK; it's the dipstick-plus-phone combo that's the problem. Together, asserts the FDA, they constitute a new medical device.

The line between app and regulated medical device has been blurry since 2011, when the FDA issued its first draft guidance. Now, everyone from app designers to Congress is awaiting the final guidance, expected this fall.

Meantime ... what do you do? A great first step: Register now for the 1-day virtual conference, Medical Device Mobile Apps.

FDAnews has invited an authoritative FDA voice, Baku Patel of CDRH, plus four top private-sector lawyers and devicemakers for an intensive one-day virtual conference. It will examine this fast-changing area, where innovation and regulation collide.


Speakers will lay out how the FDA approaches regulation of mobile medical apps, then tease out the fine points that can mean the difference between FDA approval and a warning letter. Conference attendees will discover:

- What the FDA means when it uses the word health vs. wellness
- What the FDA concept of intended use signifies
- What constitutes an accessory, and which accessories does the FDA regulate?
- Implications of the Biosence letter and the FDA's thinking going forward
- The FDA's checklist for a successful approval -- best practices and red flags every devicemaker must know
- Obtaining FDA clearance -- identifying and addressing safety-and-effectiveness criteria
- The future of mobile medical apps: How you can work with the FDA to best serve patients
- And much more

From fast-changing technology to regulatory parameters, conference chair Tim Gee is ideally positioned to shed light on the complexities. Mr. Gee has more than 20 years of in-depth research and experience helping medical device firms manage connectivity, and developing and obtaining FDA approval for medical-device apps.

Smartphone apps hold immense promise for devicemakers -- and thorny new areas of regulation and law too, as the Biosense matter illustrates. On your way to innovation, don't let regulatory hazards trip you up. Get the answers you need -- now.

Register now


- Tim Gee -- Principal/Founder of Medical Connectivity Consulting and a principal consultant with Santa Rosa Consulting. He has more than 25 years' experience with workflow automation via integration of medical devices with information systems and enabling technologies. Clients include healthcare providers, manufacturers and early-stage companies. Mr. Gee is 2012 recipient of the American College of Clinical Engineering's Challenger Award.
- Brad Thompson -- Member, Epstein Becker & Green; General Counsel, mHealth Regulatory Coalition Bakul Patel -- Senior Policy Advisor to the Center Director, CDRH, FDA (invited)
- Kyle Peterson -- Director, Regulatory & Corporate Affairs, Calgary Scientific
- Marian Lee -- Partner, King & Spalding


- Compliance officers
- Executive management
- Legal and regulatory affairs
- Manufacturing
- Outside counsel
- Product development teams
- QA/QC staff
- R&D and engineering
- Research and design teams
- Risk management and design operations


Medical Device Mobile Apps The Biosense Case: FDA Sends First Warning
**FDAnews Virtual Conference**
Oct 3 2013 -- 10 am-4 pm EDT


$1,297 per site -- includes virtual conference registration and audio CDs and transcripts


By phone: 888-838-5578 or 703-538-7600
Fax: 703-538-7676
Mail to: FDAnews, 300 N Washington St Ste 200, Falls Church VA USA 22046-3431


You must be entirely happy with this learning opportunity or FDAnews will refund your entire tuition, or extend a credit to a future FDAnews conference.


Virtual Summit registrations may not be cancelled. Registrants may substitute the 24/7 ENCORE(tm) audio and Web-based presentations for the live virtual conference at any time. Please contact Customer Service to make any substitutions. No-shows will automatically be sent the 24/7 ENCORE(TM) login information and speakers' presentations.


FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.